Know Cancer

or
forgot password


Phase 3
N/A
61 Years
Not Enrolling
Both
Multiple Myeloma

Thank you

Trial Information


Inclusion Criteria:



- patients less than 61 years of age

- Durie Salmon stage II or III

- written and informed consent

Exclusion Criteria:

- Prior treatment for myeloma

- ECOG performance score of 4

- Positive HIV test

- Chronic respiratory disease (DLco < 60%)

- Systolic ejection fraction < 50%

- Pregnant or nursing women

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Overall survival (from randomistion) of the 2 groups at 5 years

Principal Investigator

abderrahman abdelkefi

Investigator Role:

Principal Investigator

Investigator Affiliation:

Centre National de Greffe de Moelle Osseuse

Authority:

Tunisia: Ministère de la Santé Publique

Study ID:

MM01

NCT ID:

NCT00207805

Start Date:

May 2003

Completion Date:

Related Keywords:

  • Multiple Myeloma
  • Multiple Myeloma
  • Neoplasms, Plasma Cell

Name

Location